To investigate different parameters in SF of patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and osteoarthritis (OA).

**Methods** We describe the evaluation of SF in 28 SLE, 41 RA, and 36 OA patients. SF is collected via arthrocentesis in heparinized or EDTA tubes. The diagnosis was established in all subjects prior to SF examination based on typical clinical and laboratory features. The clinical activity of the diseases at the time of joint aspiration varied.

**Results** The white blood cell (WBC) count in 28 SLE patients, ranging from 500 to 12 250 with an average count of 3473 cells/µl with 55% polymorphic nuclear cells (PMNs), was significantly lower than in RA - 11 048 cells/µl with 75% PMNs. The WBC count in OA patients was significantly lower - 3718±2373 cells/µl. The highest protein levels were found in RA patients, followed by SLE and OA patients: total protein respectively 50.3±6.9 vs 45±7.3 vs 48.6±10.9 g/L and IgG concentration - 21.22±3.53 vs 9.53±4.27 vs 18±2.48 g/L. Circulating Immune Complexes were significantly higher in the RA group compared to SLE group and OA: 0.247 ±0.07 vs 0.193±0.05 vs 0.108±0.40 mg/ml.

**Conclusions** The analysis of the SF of lupus patients has shown elevated levels of WBCs, total protein and circulating immune complexes as a markers for the high SLE activity. Synovial fluid is a possibility to define the type of arthrits in different rheumatic diseases.

---

**Abstracts**

**382 ANA AND ENA TESTING ALGORITHM: PERSPECTIVE OF A LARGE PUBLIC HOSPITAL LABORATORY IN NEW ZEALAND**

K Smith*. North Shore Hospital, Special Assays, Auckland, New Zealand

10.1136/lupus-2017-000215.382

**Background and aims** An ANA and ENA testing algorithm was established at the immunology laboratory at Waitemata District Health Board (WDHB) in New Zealand. WDHB serves more than 500 000 people in central New Zealand. Due to the high demand for ANA testing, WDHB opted for an automated ANA EIA screening and Extractable Nuclear Antibodies (ENA) EIA reflex testing algorithm, with HEp-2 IFA as an option when there is a strong indication of false negative results.

**Methods** From January 2012 to April 2016, 8515 patient samples were tested with ANA Screening EIA kits, and 1624 samples were reflex tested with ENA EIA kits for detection of antibodies to SSA, SSB, Sm, Sm/RNP, Scl-70, Jo-1, dsDNA and centromere (Bio-Rad Laboratories, California, USA). The reflex testing is triggered when either the screening result was positive or requested by a clinician. ANA IFA tests were performed on request.

**Results** The general ANA screening positive rate was 18.5% (1585/8515) in the WDHB population. The positivity rate for each ENA test is shown in Table 1. The overall positive rate for individual ENA testing was 54.8% (890/1624) indicating that the ANA screening has been effective in detecting the specific presence of ENAs.

**Conclusions** Using this ANA and ENA testing algorithm, WDHB was able to screen a large number of patient samples and quickly identify specific ENA all in one day, resulting in improved workflow and significant labour and cost savings.

---

**384 MULTI-SPECIALISTS’ PERSPECTIVES ON CLINICAL DECISION MAKING IN SYSTEMIC LUPUS ERYTHEMATOSUS: AN INTERVIEW STUDY**

1D Tunnicliffe*, 3,4D Singh-Grewal, 1,3,5C Craig, 3Jjesudason, 3M.W. Lin, 6,8O’Neill, 1,2,4D Sumption, 1,2A Tong. 1University of Sydney, Sydney School of Public Health, Sydney, Australia; 2Children’s Hospital at Westmead, Centre for Kidney Research, Sydney, Australia; 3The University of Sydney, Sydney Medical School, Sydney, Australia; 4The University of New South Wales, Faculty of Medicine, Sydney, Australia; 5The Sydney Children’s Hospital Network, Department of Rheumatology, Sydney, Australia; 6Royal Adelaide Hospital, Central and Northern Adelaide Renal and Transplantation Service, Adelaide, Australia; 8Westmead Hospital, Department of Immunology, Sydney, Australia; 8Liverpool Hospital, Department of Rheumatology, Sydney, Australia

10.1136/lupus-2017-000215.384

**Background and aims** Clinicians from different medical specialists are involved in the management of patients with systemic lupus erythematosus (SLE), however, unwarranted variation in practice remains largely unexplained. This study aims to describe specialists’ attitudes and perspectives on the management of patients with SLE.